Subscribe To
ETNB / 89Bio: Let's Not Give Up Already
ETNB News
By Seeking Alpha
October 26, 2023
89bio's Low Price Presents An Opportunity
89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive more_horizontal
By GlobeNewsWire
October 17, 2023
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and more_horizontal
By The Motley Fool
October 10, 2023
Why Shares of 89bio Plummeted on Tuesday
89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic diseases. more_horizontal
By Proactive Investors
August 28, 2023
89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic
Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from th more_horizontal
By Seeking Alpha
August 10, 2023
89bio, Inc.: A Big Bet On NASH
89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-li more_horizontal
By Market Watch
June 13, 2023
89bio shares rise as analysts see improved outlook for NASH treatments
Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the more_horizontal
By Zacks Investment Research
May 29, 2023
89BIO (ETNB) Just Overtook the 20-Day Moving Average
89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB crossed a more_horizontal
By Seeking Alpha
May 28, 2023
89bio: Great Prospects After Excellent Phase 2 Data
ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now. more_horizontal
